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Background: We previously identified TrkB as an oncogene involved in promoting metastasis in endometrial
carcinoma (EC). Here, we sought to delineate the effect of changes in TrkB expression on the global profile of
microRNAs (miRNAs) in EC cells and further investigated the correlation between the expression of certain miRNA
and TrkB in the clinicopathologic characteristics of EC patients.
Methods and results: Using quantitative reverse transcription-PCR (qRT-PCR), we found that expression of TrkB
mRNA has no significant difference in transcript levels between normal endometrium and EC cells captured by laser
capture microdissection, while immunohistochemistry results demonstrated a markedly higher expression of TrkB
protein in EC tissues. The microRNA array showed that ectopic overexpression and knockdown of TrkB expression
caused global changes in miRNA expression in EC cells. qRT-PCR results showed that elevated TrkB repressed
miR-204-5p expression in EC cells. Furthermore, immunoblotting assays revealed that TrkB overexpression in
IshikawaTrkB cells noticeably increased JAK2 and STAT3 phosphorylation, which, however, was aborted by TrkB
knockdown in HEC-1BshTrkB cells. Moreover, ChIP assays showed that phospho-STAT3 could directly bind to
STAT3-binding sites near the TRPM3 promoter region upstream of miR-204-5p. Interestingly, using bioinformatics
analysis and luciferase assays, we identified TrkB was a novel target of miR-204-5p. Functionally, the MTT assays,
clonogenic and Transwell assays showed that miR-204-5p significantly suppressed the clonogenic growth, migration
and invasion of EC cells. Furthermore, miR-204-5p also inhibited the growth of tumor xenografts bearing human EC
cells. Importantly, we found lower miR-204-5p expression was associated with advanced FIGO stages, lymph node
metastasis and probably a lower chance for survival in EC patients.
Conclusions: This study uncovers a new regulatory loop involving TrkB/miR-204-5p that is critical to the
tumorigenesis of EC and proposes that reestablishment of miR-204-5p expression could be explored as a potential
new therapeutic target for this disease.
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Endometrial carcinoma is the most common gynecological
malignancy worldwide. For 2013, in the USA alone, 49,560
persons will be newly diagnosed with endometrial car-
cinoma and 8,190 persons will die of this disease [1].
Hysterectomy with or without adjuvant treatment has
been recommended for local endometrial carcinoma, yield-
ing a 5-year survival rate of approximately 96%. However,
30% endometrial carcinoma cases are not diagnosed until
regional or distant metastasis is present, resulting in a much
more dismal outcome [2]. Thus, identification of additional
molecular and cellular mechanisms responsible for tumori-
genesis and progression of endometrial cancer, and dis-
covery of novel diagnostic and prognostic biomarkers
and development of novel therapeutic strategies for endo-
metrial cancer are critical to improving the diagnosis and
prognosis of endometrial cancer patients.
Endometrial cancer was originally classified according
to a dualistic model [3]. More recently, this model has
been challenged because tumors seen in daily practice
occasionally show overlapping or combined morpho-
logic and molecular characteristics of both classification
types or exhibit ambiguous features [4]. In endometrial
cancer, myometrial invasion and lymph node metastasis
are considered the most important prognostic factors [5].
For these processes to occur, epithelial tumor cells need
to undergo an epithelial to mesenchymal transition (EMT)
[6]. Neurotrophic receptor tyrosine kinase B (TrkB) has
been shown to be a key regulator of oncogenesis and tumor
progression in various human cancer types including can-
cer of the lungs and breast [7,8]. We have also previously
demonstrated a novel role of TrkB in promoting EMT and
resistance to anoikis [9]. As an additional receptor tyrosine
kinase, TrkB activates diverse downstream signaling cas-
cades that ultimately induce cellular proliferation and
pro-survival mechanisms through the AKT, STAT3 and
MAPK signaling pathways [10,11].
MicroRNAs (miRNAs) are small non-coding ribonucleic
acids (RNAs) of approximately 22 bp that induce RNA
interference by base-pairing with the 3′ untranslated region
(UTR) of a complementary messenger RNA (mRNA),
which triggers either mRNA translational repression
or RNA degradation [12]. Approximately 20–30% of
all genes are targeted by miRNAs, and a single miRNA
may target as many as 200 genes [13]. In human cancers,
specific miRNAs are expressed in different tissues, and
changes in the regulation of gene expression have been
associated with carcinogenesis [14], including endomet-
rial cancer [15]. Furthermore, miRNAs cooperatively
function with certain transcription factors in the regula-
tion of mutual sets of target genes, allowing coordinated
modulation of gene expression both transcriptionally
and posttranscriptionally. Specifically, a recurring network
motif has been revealed in which a transcription factorregulates a miRNA with which it cooperates in regulating
a common set of targets [16]. These observations prompted
us to hypothesize that specific miRNAs may control
TrkB expression posttranscriptionally in endometrial
cancer progression.
Here, we report the identification of a set of miRNAs
repressed by TrkB in two endometrial cancer cell lines
by comprehensive miRNA profiling. One candidate miRNA
of interest, miR-204-5p, is located at the cancer-associated
genomic region 9q21.1–q22.3 locus and is known to be
significantly dysregulated in broad tumor types, including
breast, prostate, and kidney cancers [17], suggesting a role
for miR-204-5p as a tumor suppressor gene. We demon-
strate a role for miR-204-5p in endometrial cancer and
also shed light on a novel posttranscriptional regulatory
circuit in which TrkB induces the activation of STAT3 to
regulate the expression of miR-204-5p, which in turn, dir-
ectly modulates TrkB expression in endometrial cancer
cells. These results establish miR-204-5p as a novel TrkB
regulator and a potential therapeutic target for EC.
Results
TrkB overexpression is associated with global changes in
miRNA expression in endometrial cancer cells
We examined TrkB protein and mRNA expression in
the normal endometrium and endometrial cancer tissues
using laser capture microdissection (LCM)/quantitative
reverse transcription polymerase chain reaction (qRT-PCR)
and immunohistochemistry. Our RT-PCR assays of normal
and endometrial cancer cells captured by LCM (Figure 1A)
revealed that mRNA transcript levels of TrkB appeared to
be higher in the tumors than in the normal specimens, but
overall the difference in TrkB mRNA expression between
endometrial cancer tissues and the normal endometrium
was not statistically significant (P > 0.05) (Figure 1B).
Immunohistochemistry, on the other hand, demonstrated
a markedly higher expression of TrkB in endometrial
cancer tissues compared with the normal endometrium
(P < 0.0001) (Figure 1C). The data suggest that TrkB is
upregulated mainly at the posttranscriptional level in
human endometrial cancer tissues.
We were interested in whether changes in TrkB expres-
sion impacted on the global profile of miRNA expression in
endometrial cancer cells. Our microRNA array consisting of
1347 capture probes for mature human miRNAs showed
marked changes in the expression of 98 miRNAs in HEC-
1BshTrkB cells whose TrkB expression was suppressed by
short hairpin RNA (shRNA) against TrkB compared to
HEC-1B cells (Figure 1D). TrkB overexpression also caused
marked changes in 126 miRNAs in IshikawaTrkB cells ectopi-
cally expressing TrkB compared to Ishikawa cells (Figure 1D).
Consistently, 76 miRNAs were found among the differen-
tially expressed miRNAs in both HEC-1BshTrkB cells (77.6%,
76/98) and IshikawaTrkB cells (60.3%, 76/126) (Table 1).
Figure 1 TrkB overexpression is associated with global changes in miRNA expression in endometrial cancer cells. (A) Laser capture
microdissection (LCM) of normal (N) endometrial cells and endometrial cancer (EC) cells. 100×. (B) Quantitative reverse transcription polymerase
chain reaction (qRT-PCR) of TrkB in endometrial cancer specimens (n = 71) and normal tissues (n = 25). TrkB expression was normalized against
β-actin. Data are presented as individual samples with the line indicating the mean +/− SD. NS, P > 0.05. (C) Immunostaining scores of TrkB in
normal endometrium (n = 25) and endometrial cancer specimens (n = 110). Data are presented as mean +/− SD. **, P < 0.01. (D) MicroRNA array
analysis of miRNA expression in endometrial cancer cells. Hierarchical clustering of the expression values for 1347 mature miRNAs of IshikawaTrkB
versus Ishikawa cells and HEC-1BshTrkB versus HEC-1B cells.
Bao et al. Molecular Cancer 2013, 12:155 Page 3 of 19
http://www.molecular-cancer.com/content/12/1/155MiR-204-5p is a negative modulator of TrkB expression in
endometrial cancer cells
Separately, we surveyed the 3′-UTR of the TrkB promoter
using three target-prediction algorithms, TargetScan, Pictar
and MiRanda, to identify candidate miRNAs which may act
as posttranscriptional modulators of TrkB expression.
TargetScan, Pictar and MiRanda revealed 4, 3 and 37
candidate miRNAs, respectively (Figure 2A). Examination
of the 76 differentially expressed miRNAs as identified
by microarray analysis showed that miR-211-5p and
miR-204-5p were the only two candidate miRNAs that
were also identified by all three target-prediction algorithms
to potentially bind to the 3′-UTR of the TrkB (Figure 2A).
Furthermore, the miR-204-5p targeting site within the3′UTR of TrkB (position 457–464) was highly conserved
across five mammalian species (Additional file 1: Figure
S1A). These intriguing findings suggest that miR-211-5p
and miR-204-5p and TrkB are likely mutual modula-
tors of their expression.
MiR-204-5p is reportedly dysregulated in endometrial car-
cinoma [18,19]. To examine whether miR-204-5p modulated
TrkB expression, we constructed vectors containing a
wildtype or mutant TrkB 3′UTR directly fused down-
stream of the Firefly luciferase reporter gene (Figure 2B).
The wildtype or mutant vector was co-transfected into
293 T cells with miR-204-5p mimic (miR-204 m) or its
scrambled control (miR-204 m NC). Co-transfection assays
showed that, compared with the scrambled miRNA control,
Table 1 Microarray profiling of changes in global miRNA expression in endometrial cancer cells with high or low TrkB
expression
MiRNA Fold change MiRNA Fold change
IshikawaTrkB vs. Ishikawa HEC-1BshTrkB vs. HEC-1B
Downregulated Upregulated
hsa-miR-1 −1.53 hsa-miR-1 1.84
hsa-miR-103b −1.53 hsa-miR-103b 1.84
hsa-miR-103a-2-5p −1.53 hsa-miR-103a-2-5p 1.84
hsa-miR-1178 −1.53 hsa-miR-1178 1.84
hsa-miR-1179 −1.53 hsa-miR-1179 1.84
hsa-miR-1180 −1.53 hsa-miR-1180 1.84
hsa-miR-124-5p −1.53 hsa-miR-124-5p 1.84
hsa-miR-1243 −1.53 hsa-miR-1243 1.84
hsa-miR-1245a −1.53 hsa-miR-1245a 1.84
hsa-miR-1270 −1.53 hsa-miR-1270 1.84
hsa-miR-133a −1.53 hsa-miR-133a 1.84
hsa-miR-133b −1.53 hsa-miR-133b 1.84
hsa-miR-150-5p −1.53 hsa-miR-150-5p 1.84
hsa-miR-200c-3p −1.56 hsa-miR-200c-3p 1.84
hsa-miR-204-5p* −1.53 hsa-miR-204-5p* 1.84
hsa-miR-21-3p −5.95 hsa-miR-21-3p 1.97
hsa-miR-211-5p* −1.53 hsa-miR-211-5p* 1.84
hsa-miR-222-5p −1.53 hsa-miR-222-5p 1.84
hsa-miR-300 −1.53 hsa-miR-300 1.84
Upregulated Downregulated
hsa-let-7a-5p 1.52 hsa-let-7a-5p −1.51
hsa-let-7c 1.53 hsa-let-7c −1.66
hsa-miR-101-3p 1.52 hsa-miR-101-3p −2.13
hsa-miR-107 1.52 hsa-miR-107 −1.53
hsa-miR-1202 1.53 hsa-miR-1202 −1.52
hsa-miR-1246 2.83 hsa-miR-1246 −1.68
hsa-miR-126-3p 5.39 hsa-miR-126-3p −2.66
hsa-miR-128 1.69 hsa-miR-128 −1.51
hsa-miR-200a-5p 2.05 hsa-miR-200a-5p −2.04
hsa-miR-200b-3p 1.87 hsa-miR-200b-3p −1.51
hsa-miR-425-5p 1.51 hsa-miR-425-5p −1.59
*predicted to bind to TrkB 3′-UTR by TargetScan, Pictar and MiRanda.
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activities of 293 T cells transfected with the wildtype TrkB
3′UTR (P < 0.01) (Figure 2B). No reduction in luciferase
activities was observed of 293 T cells transfected with the
mutant TrkB 3′UTR.
Our finding that TrkB may be targeted by miR-204-5p
led us to further delineate the actions of miR-204-5p on
TrkB in endometrial cancer cells. Our RT-PCR assays
revealed that IshikawaTrkB cells transfected with miR-
204-5 m had markedly reduced TrkB mRNA transcriptlevels compared to IshikawaTrkB cells transfected with
scrambled miRNA (P < 0.01) (Figure 2C). Immunoblotting
assays also showed that IshikawaTrkB cells transfected with
miR-204 m had markedly reduced TrkB levels (P < 0.05)
(Figure 2D and E). Furthermore, HEC-1BshTrkB cells
transfected with a miR-204-5p inhibitor (miR-204i) had
markedly higher TrkB mRNA transcript levels than
HEC-1BshTrkB cells transfected with scrambled miRNA
(P < 0.01) (Figure 2F). Our immunoblotting assays
additionally showed that HEC-1BshTrkB cells transfected
Figure 2 (See legend on next page.)
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Figure 2 MiR-204-5p is a negative modulator of TrkB expression in endometrial cancer cells. (A) Schema of selection of candidate miRNAs
(miR-211-5p and miR-204-5p) targeting TrkB using three online target-prediction programs (TargetScan, Pictar and miRanda) and the microarray data. (B) Left
panel: Schema of the construction of pMIRGLO-TrkB-3′UTR-WT and pMIRGLO-TrkB-3′UTR-MT vectors. The mutant binding site is underlined. Right panel:
293 T cells were co-transfected with pMIRGLO-TrkB-3′UTR-WT or pMIRGLO-TrkB-3′UTR-MT and miR-204-5p mimic (miR-204 m) or scrambled miRNA control
(miR204m NC). Luciferase activities are shown as mean ± SD of at least three independent experiments done in triplicate. ** P < 0.01. (C) IshikawaTrkB cells
were transfected with miR-204 m NC or miR-204 m. TrkB expression was examined by RT-PCR and normalized against β-actin. Data are shown as
mean ± SD of at least three independent experiments.** P < 0.01; NS P> 0.05. (D) Cells were transfected as in (C) and TrkB expression was determined by
Western blotting assays, which were quantified by densitometry of triplicate experiments (* P < 0.05; NS P > 0.05). β-actin was included as
an internal control. Representative blots are shown in (E). (F) HEC-1BshTrkB cells were transfected with a miR-204 inhibitor (miR-204i) or a
scrambled control inhibitor (miR-204i NC) or with miR-204 inhibitor (miR-204i). TrkB expression was examined by RT-PCR and normalized
against β-actin. Data are shown as mean ± SD of at least three independent experiments.** P < 0.01; NS P > 0.05. (G) Cells were transfected
as in (F) and TrkB expression was determined by Western blotting assays, which were quantified by densitometry of triplicate experiments
(** P < 0.01; NS P > 0.05). β-actin was included as an internal control. Representative blots are shown in (H).
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TrkB (P < 0.01) (Figure 2G and H). These findings in-
dicated that miR-204-5p negatively regulated the expres-
sion of TrkB.
TrkB represses miR-204-5p expression by activating the
JAK2/STAT3 pathway in vitro
Our microRNA microarray showed that miR-204-5p was
downregulated in IshikawaTrkB cells. Further examination
by qRT-PCR assays revealed that miR-204-5p expression
was noticeably suppressed in IshikawaTrkB cells (vs. Ishikawa
cells, P < 0.01), but markedly enhanced in HEC-1BshTrkB
cells (vs. HEC-1B cells, P < 0.01) (Figure 3A). These results
further corroborated the microRNA array findings and in-
dicated that TrkB suppresses miR-204-5p expression. Our
qRT-PCR assays also showed that the mRNA transcript
levels of TRPM3, which shares the same regulatory motif for
transcription with miR-204 [17], were significantly decreased
in IshikawaTrkB cells (P < 0.05), but markedly elevated in
HEC-1BshTrkB cells (P < 0.01) (Figure 3B), lending support to
an inhibitory role of TrkB at the TRPM3/miR-204-5p locus.
The TrkB signaling pathway overlaps with the ERK/
MAPK or JAK2/STAT3 signaling pathway in myeloma
or endometrial cancer cells [20,21], which prompted us
to examine whether TrkB suppressed miR-204-5p expres-
sion via these signaling pathways. Our immunoblotting as-
says revealed that TrkB overexpression in IshikawaTrkB cells
noticeably increased the phosphorylation of JAK2 and
STAT3, which, however, was aborted by TrkB knockdown
in HEC-1BshTrkB cells (Figure 3C). No obvious activation
was found by TrkB overexpression in ERK/MAPK pathway
(Figure 3C), and effect of its inhibition (U0126 10 μM) on
miR-204-5p expression (Additional file 2: Figure S2A-C).
Moreover, inhibition of STAT3 by small interference RNA
(siRNA) (Figure 3D) elevated the miR-204-5p expression in
IshikawaTrkB and HEC-1B cells (P < 0.05) (Figure 3E),
indicating that, indeed, TrkB activates the JAK2/STAT3
pathway in endometrial cancer cells. We further examined
whether phospho-STAT3 could bind to three putative
STAT-binding sites that are located near the TRPM3promoter region upstream of miR-204-5p [22] (Figure 3F).
Our ChIP assays showed that phospho-STAT3 could bind
to all the three putative STAT-binding sites in Ishika-
waTrkB and HEC-1B cells, with the greatest binding to
DW2 (Figure 3G). These data together suggest that TrkB
overexpression upregulates the phosphorylation levels of
STAT3, which binds to the STAT-binding sites near the
TRPM3 promoter region upstream of miR-204-5p,
leading to repression of miR-204 in endometrial cancer
cells.
TrkB promotes while miR-204-5p suppresses the
clonogenic growth, migration and invasion of
endometrial cancer cells in vitro
To investigate whether miR-204-5p modulated the growth
of endometrial cancer cells, we transfected IshikawaTrkB
cells with miR-204 m or its scrambled control and HEC-
1BshTrkB cells with miR-204i or its scrambled control. The
MTT assays showed that compared with Ishikawa cells,
IshikawaTrkB cells, which had markedly reduced miR-204-
5p as measured by TaqMan PCR assays (Figure 4A, left
panel), exhibited significantly increased growth (P < 0.05)
(Figure 4A, right panel). Treatment with miR-204 m, how-
ever, significantly attenuated the growth of IshikawaTrkB cells
(vs. scrambled control or non-transfected cells, P < 0.05)
(Figure 4A, right panel). Conversely, compared to HEC-1B
cells, HEC-1BshTrkB cells, which had markedly increased
miR-204-5p as measured by TaqMan PCR assays (Figure 4B,
left panel), showed markedly reduced growth (P < 0.05)
(Figure 4B, right panel). Treatment with miR-204i partially
and yet significantly rescued the growth of HEC-1BshTrkB
cells (vs. scrambled control or non-transfected cells,
P < 0.05) (Figure 4B, right panel). Furthermore, the
clonogenic assays showed that miR-204 m caused a
greater than 50% reduction in the number of colonies com-
pared with that of IshikawaTrkB cells or IshikawaTrkB cells
transfected with the scrambled control (P < 0.01 in both)
(Figure 4C, Additional file 3: Figure S3A). By contrast,
miR-204i noticeably increased the number of colonies
compared with that of HEC-1BshTrkB cells or HEC-1BshTrkB
Figure 3 (See legend on next page.)
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Figure 3 TrkB represses miR-204-5p expression by activating the JAK2/STAT3 pathway. (A) TrkB inversely regulates miR-204-5p expression
and (B) TRPM3 mRNA expression in endometrial cancer cells. MiR-204-5p and TRPM3 mRNA levels in Ishikawa and IshikawaTrkB cells and HEC-1B
and HEC-1BshTrkB cells were measured by quantitative RT-PCR. MiR-204-5p expression was normalized against U6B and TRPM3 mRNA expression
was normalized against β-actin. Data are expressed as mean ± SD of at least three independent experiments. **P < 0.01 and *P < 0.05. (C) TrkB,
phospho-TrkB, phospho-P44/42, P44/42, JAK2, STAT3, phospho-JAK2 and phospho-STAT3 in Ishikawa and IshikawaTrkB cells and HEC-1B and
HEC-1BshTrkB cells were assessed by Western blotting assays. Representative blots are shown. Blue arrows show the opposite changes in the two
cell lines. (D) IshikawaTrkB and HEC-1B cells were transfected with siSTAT3, and phospho-STAT3 was assessed by Western blotting assays. (E) Inhibition
of STAT3 increases miR-204-5p expression in IshikawaTrkB and HEC-1B cells. Data are expressed as mean ± SD of at least three independent experiments.
*P < 0.05. (F) Schematic representation of the miR-204-5p locus and its host gene, TRPM3. STAT3-binding sites around the TRPM3 start site (UP1, DW1,
and DW2) are predicted by in silico analysis. Chromatin immunoprecipitation assays were performed using anti-phospho-STAT3 antibody or rabbit
isotype IgG. Immunoprecipitated DNA fragments were examined by quantitative real-time PCR (G). Data in (G) represent mean ± SD of at least three
independent experiments performed in triplicate. VEGF was used as positive control and IgG as negative control.
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both) (Figure 4C, Additional file 3: Figure S3A). These
results suggest that TrkB promotes while miR-204-5p sup-
presses the clonogenic growth of endometrial cancer cells.
We further assessed whether miR-204-5p modulated
the migratory and invasive capacity of endometrial can-
cer cells. Our Transwell assays showed that IshikawaTrkB
cells displayed an enhanced capacity of migration compared
to Ishikawa cells, which, however, was markedly abated
by miR-204 m (vs. non-transfected or scrambled con-
trol, P < 0.05) (Figure 4D, Additional file 3: Figure S3B).
Conversely, HEC-1BshTrkB cells exhibited reduced migration
capacity compared to HEC-1B cells, which was en-
hanced by miR-204i (vs. non-transfected or scrambled
control, P < 0.05) (Figure 4E, Additional file 3: Figure S3B).
Furthermore, similar findings were observed in invasion
assays of IshikawaTrkB cells and HEC-1BshTrkB cells
(Figure 4F and G, Additional file 3: Figure S3C). These
results together demonstrate that TrkB increases while
miR-204-5p suppresses the clonogenic growth, migration
and invasion of endometrial cancer cells in vitro.
TrkB is a functionally important target of miR-204-5p
involved in the clonogenic growth, migration and
invasion of endometrial cancer cells in vitro
MiRNAs can target a series of mRNAs representing
anywhere from several to hundreds of genes. To address
whether the phenotypic effects of miR-204-5p expression
are predominately due to the suppression of TrkB, rather
than one of its other cellular targets, we additionally
examined whether miR-204-5p and TrkB functioned in
the same pathway in modulating clonogenic growth,
migration and invasion of endometrial cancer cells. We
abolished miR-204-5p activity by transfecting Ishikawa
cells with miR-204i. The RT-PCR and Western blotting
assays showed that in miR-204i-transfected cells, co-
transfection with siTrkB significantly reduced TrkB ex-
pression as compared to co-transfection with siTrkB
NC (Figure 5A). Furthermore, in the absence of miR-204-5p activity, the number of colonies in Ishikawa cells
was increased (P < 0.01), while silencing of TrkB by specific
siRNA resulted in a marked reduction in the number of
colonies compared with the scrambled control (P < 0.01)
(Figure 5B); and a similar reduction was observed in the
number of migrated and invasive cells (P < 0.01) (Figure 5C
and D). Furthermore, we chose Ishikawa cells, who do
not express TrkB to see if miR-204-5p alone exerted any
functional effect on EC cell lines. As expected, cells treated
with miR-204 m had no obvious change in cellular pro-
liferation, colony formation, migration and invasion com-
pared with wildtype Ishikawa cells (Figure 5E-H). Together,
these results suggest that TrkB is a functionally important
downstream target of miR-204-5p that is involved in the
clonogenic growth, migration and invasion of endometrial
carcinoma cells.
MiR-204-5p inhibits the growth of mouse xenografts
bearing human endometrial carcinoma cells
We were interested in whether miR-204-5p suppressed the
growth of xenografts bearing human endometrial carcinoma
cells. We transfected IshikawaTrkB cells with miR-204-5p
precursor or its scrambled control using lentiviruses
(Figure 6A, Additional file 4: Figure S4A). Compared to the
scrambled control, mouse xenografts bearing IshikawaTrkB
cells overexpressing miR-204-5p showed a dramatic reduc-
tion in tumor size (P < 0.05) (Figure 6B and C) and tumor
weight (P < 0.05) (Figure 6D). To verify its effects on protein
expression, tumor tissue was embedded in paraffin and then
stained with hematoxylin and eosin (H&E) for histological
examination. As expected, TrkB and phospho-STAT3 levels
were detectable in the control xenografts; however, the
miR-204 expressing tumors had significantly lower levels of
these proteins (Figure 6E, first four pairs of panels), thus
verifying its role as a negative regulator of the TrkB/STAT3
pathway in vivo.
To determine whether miR-204-5p expression affects
the in vivo proliferative ability of endometrial carcinoma
cells, we examined the expression of two proliferation
Figure 4 TrkB promotes while miR-204-5p suppresses the clonogenic growth, migration and invasion of endometrial cancer cells. (A)
Left panel: IshikawaTrkB cells were transfected with miR-204 m or miR-204 m NC. MiR-204-5p expression was measured by TaqMan PCR assays
72 h post transfection and normalized against U6B. Data are shown as mean ± SD of at least three independent experiments. ** P < 0.01; NS, P > 0.05.
Right panel: The growth curves of Ishikawa cells were plotted by MTT assays. Data are shown as mean ± SD of at least three independent experiments.
* P < 0.05; NS, P > 0.05. (B) Left panel: HEC-1BshTrkB cells were transfected with miR-204i or miR-204i NC. MiR-204-5p expression was measured by
TaqMan PCR assays 72 h post transfection and normalized against U6B. Data are shown as mean ± SD of at least three independent experiments.
** P < 0.01 vs. miR-204i; NS, P > 0.05. Right panel: The growth curves of HEC-1B cells were plotted by MTT assays. * P < 0.05; NS, P > 0.05. (C) IshikawaTrkB
cells were transfected as in (A) and HEC-1BshTrkB cells as in (B). Colony formation was observed. Data are shown as mean ± SD of at least three
independent experiments. ** P < 0.01; NS P > 0.05. (D to G) IshikawaTrkB cells were transfected with miR-204 m or miR-204 m NC and HEC-1BshTrkB cells
with miR-204i or miR-204i NC. Transwell and cell invasion assays were done as described in Methods. The number of migrated cells is shown in
(D and E, * P < 0.05; NS, P > 0.05). The number of invasive cells is shown in (F and G, * P < 0.05; NS, P > 0.05).
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Figure 5 TrkB is a functionally target of miR-204-5p involved in the clonogenic growth, migration and invasion of endometrial cancer
cells. (A) Upper panel, Ishikawa cells were co-transfected with miR-204i or its scrambled control and siTrkB or its scrambled control. Expression of
TrkB mRNA in Ishikawa cells was measured by RT-PCR assays at 48 h posttransfection. Lower panel, TrkB protein levels were measured by western
blotting assays at 72 h posttransfection. Cologenic assays were done as described in Methods and are shown in (B). (C) Migrated and invasive
cells on the lower surface of the Transwell filter were stained and photographed, 200×. The number of migrated and invasive cells is shown in
(D). (E) Ishikawa cells were transfected with miR-204 m, and the growth curves of Ishikawa cells were plotted by MTT assays. (F) Colony formation
was observed. Transwell and cell invasion assays were done as described in Methods. The number of migrated and invasive cells is shown in
(G and H). In all the panels, data are shown as mean ± SD of at least three independent experiments. * P < 0.05, ** P < 0.01; NS P > 0.05.
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Figure 6 MiR-204-5p inhibits the growth of mouse xenografts bearing human endometrial carcinoma cells. (A) IshikawaTrkB cells were
transfected with lentiviruses encoding miR-204 or its scrambled control (NC). MiR-204 was detected by TaqMan PCR and normalized against U6B.
Data are expressed as mean ± SD of at least three independent experiments. ** P < 0.01. (B) Tumor growth curve in nude mice bearing IshikawaTrkB
cells transfected with lentiviruses encoding miR-204 or its scrambled control. Data are expressed as mean ± SD of 8 mice. * P < 0.05. (C) Photograph of
tumor xenografts. (D) Tumor weights are expressed as mean ± SD of tumors from panel C. *P < 0.05. (E) Representative H&E staining histopathology
of miR-204 NC and miR-204 tumor tissues in mice (left panels). MiR-204 expression was detected by in situ hybridization (second panels), and TrkB,
p-STAT3, Ki 67 and PCNA expression was detected by immunohistochemistry (right panels) (magnification, 200×). Results are representative of three
independent experiments.
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staining (Figure 6E, last two pairs of panels). The ki67
proliferation index of the NC group [(92.80 ± 3.24)%]
was markedly greater than that of the miR-204-5p group
[(52.76 ± 9.62)%; P < 0.05]. Consistently, the PCNA pro-
liferation index of the NC group [(91.30 ± 6.75)%] was
significantly higher than that of the miR-204-5p group
[(20.60 ± 11.46)%; P < 0.05], (Additional file 4: Figure S4B).
These results indicate that miR-204-5p inhibits the tumori-
genicity of endometrial carcinoma cells in vivo and further
suggests a tumor-suppressive effect of miR-204-5p via
the TrkB/STAT3 pathway.
MiR-204-5p expression correlates with tumor stage and
lymph node metastasis of endometrial cancer patients
To further determine the correlation between the clinico-
pathologic characteristics of endometrial cancer patients
and miR-204-5p expression, we measured the expression
levels of miR-204-5p in 25 normal endometrium samples
and 71 endometrial cancer tissues by TaqMan PCR assays.
We observed a significantly lower expression of miR-204-
5p in endometrial cancer tissues compared with thenormal endometrium (P < 0.0001) (Figure 7A). Moreover,
Spearman correlation analysis showed a strong inverse
correlation between the expression of TrkB and miR-204-
5p (r = −0.2414, P < 0.05) (Figure 7B). Our RT-PCR assays
further showed increasingly lower miR-204-5p levels as
tumors progressed from FIGO stage I to III (stage I vs. III,
P < 0.05) (Figure 7C). Though miR-204-5p levels were
lower in type II vs. I tumors and tumors with myometrial
invasion, no statistical association was observed between
miR-204-5p expression and histological type, tumor grade,
or myometrial invasion (P > 0.05) (Figure 7D-F). However,
a statistically significant association was observed between
miR-204-5p expression and lymph node metastasis with
tumors showing positive lymph node metastasis having
markedly lower levels of miR-204-5p (P < 0.05) (Figure 7G).
Furthermore, analysis of the correlation of miR-204 ex-
pression and the overall survival (OS) of uterine corpus
endometrioid carcinoma (UCEC) patients (n = 279) in an
independent dataset from the Cancer Genome Atlas net-
work further showed that though UCEC patients with
high mR-204 expression exhibited a higher rate of OS, no
significant difference in OS was noted between UCEC
Figure 7 MiR-204-5p expression correlates with tumor stage and lymph node metastasis of endometrial cancer patients. (A) MiR-204-5p
expression in endometrial cancer tissue specimens (n = 71) and normal endometrium (N) (n = 25) was assessed by RT-PCR and normalized
against U6B expression. ** P < 0.0001, unpaired Student’s t test. (B) Spearman correlation analysis of TrkB expression by immunohistochemistry
and miR-204-5p expression by RT-PCR of 71 endometrial cancer tissue specimens. Furthermore, miR-204 expression by RT-PCR was stratified by
FIGO stage (C), histological type (D), grade in type I (E), myometrial invasion (F), and lymph node status (G). *P < 0.05; NS P > 0.05. Bars show
mean ± SD. (H) The Kaplan–Meier overall survival (OS) of uterine corpus endometrioid carcinoma patients (n = 279) from a dataset in the Cancer
Genome Atlas stratified by miR-204-5p expression. P = 0.119.
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(Figure 7H). However, high mR-204 expression was found
to be associated with a higher likelihood of survival for
UCEC patients (OS; 1.3164). These findings demonstrated
that lower miR-201-5p expression is associated with ad-
vanced FIGO stages, lymph node metastasis and probably
a lower chance for survival in endometrial cancer patients.
Discussion
The current study identifies a novel TrkB–STAT3–miR-
204-5p signaling axis that plays an important role in endo-
metrial carcinoma growth through the accumulation of thekey tumor oncogene TrkB (Figure 8). In addition, this
study provides a comprehensive mechanism in the
tumorigenesis of endometrial carcinoma for TrkB in in-
ducing phosphorylation of STAT3 to regulate the ex-
pression of miR-204-5p, which, in turn, controls TrkB
expression. Our results suggest that the TrkB/miR-204
pathway may serve as a novel therapeutic target for endo-
metrial carcinoma, a disease characterized by remarkable
lymph node metastasis and dismal prognosis. The infor-
mation gained from this research is of important clinical
implications for patients with endometrial cancer, as well
as other cancer types associated with elevated TrkB
Figure 8 The TrkB–STAT3–miR-204-5p regulatory circuit in
endometrial cancer. Left: In normal cells, a recurrent auto-regulatory
circuit involving the expression of TrkB induces phosphorylation of
STAT3 to negatively regulate the expression of miR-204-5p.
MiR-204-5p, in turn, represses TrkB expression. The expression of
miR-204 within this circuit maintains endometrial cells in a normal
differentiated state. Right: In endometrial cancer cells, this circuit
becomes dysregulated due to increased activity of the TrkB–STAT3
component of the circuit, which constitutively represses miR-204-5p. In
the absence of sufficient miR-204 tumor suppressor activity, TrkB is left
uncontrolled, thereby leading to carcinogenesis.
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diseases with dysregulated expression of TrkB.
Tumor dissemination and metastasis are the leading
causes of death in endometrial cancer. Acquired expression
of certain Trk family members (TrkA and TrkC) in various
cancer types can be a good prognostic indicator [23].
However, elevated expression of TrkB has been associated
with poor survival of breast cancer patients [24]. A role for
TrkB in preventing anoikis was revealed in an unbiased
screen of rat intestinal epithelial cells [10] and TrkB was
shown to induce a profound morphological change in
which the expression of epithelial markers was reduced
and the expression of mesenchymal markers was enhanced
[25,26]. TrkB is proposed to function as a key regulator of
oncogenesis and tumor progression in a variety of human
cancers, including lung [7], breast [8], pancreatic [27],
stomach [28], colon [28,29], prostate [30], and ovarian
cancer [31]. In our previous study, we confirmed that
stimulation with brain-derived neurotrophic factor (BDNF),
a natural ligand for TrkB, enhances TrkB-mediated endo-
metrial carcinoma cell survival. The kinase activity of TrkB
contributes to endometrial carcinoma progression by
inhibiting anoikis and promoting EMT [9]. In the present
study, TrkB mRNA appeared to have no obvious change
between endometrial carcinoma and normal tissues while
TrkB protein levels varied markedly between endometrial
carcinoma and normal tissues. This observation led us
to hypothesize that TrkB expression is upregulated via
a posttranscriptional mechanism in endometrial carcin-
oma progression.Epigenetic effects are a key aspect of the relationship
between miRNAs and carcinogenesis [32]. Dysregulated
expression of miRNAs has recently been associated with
carcinogenesis in endometrial carcinoma [18,33,34]. Onco-
genesis may involve complex patterns of regulation because
tumor suppressor miRNAs themselves are subject to
transcription factor regulation, in addition to their epigen-
etic regulation of oncogenes or tumor suppressor genes
[35]. These findings provide a new perspective on TrkB-
induced metastasis. In the present study, we explored
TrkB-dependent regulation of miRNA expression in two
pairs of endometrial carcinoma cell lines via comprehensive
miRNA profiling analysis. We provide evidence that
miR-204-5p, which acts as a potent tumor growth and
metastasis suppressor both in vitro and in vivo, is somatic-
ally lost in human endometrial carcinoma. The finding that
miR-204-5p is downregulated in endometrial carcinoma is
intriguing, as decreased miR-204-5p levels have been
reported in several types of solid tumors [36-38], and
suggests that loss of miR-204-5p may be a common event
in tumorigenesis.
STAT3 is classified as a proto-oncogenic transcription
factor, and constitutive activation of STAT3 has been
frequently detected in various types of human cancers
including endometrial carcinoma [39]. We and others
have shown that as a receptor tyrosine kinase, TrkB acti-
vates downstream signaling cascades that ultimately induce
cellular proliferation through the STAT3 signaling pathways
[20]. To date, many studies have focused on miRNAs and
their regulated targets, but few studies have investigated
how miRNA expression is controlled transcriptionally [40].
In this study, we show that reduction of miR-204 correlates
with phosphorylation of STAT3, which directly binds to
the regulatory sites of its host gene, TRPM3, suggesting
a regulatory mechanism for TrkB in controlling miR-204
levels through STAT3 activation. Interestingly, TRPM3 is
a member of the transient receptor potential melastatin
(TRPM) family, which has also been reported to be associ-
ated with cancer progression. Downregulation of TRPM1/
melastatin mRNA in primary malignant melanoma is
a prognostic marker for metastasis [41]; however, the
pathobiologic role of TRPM3 in endometrial carcinoma
remains largely unknown. Whether TRPM3 and miR-
204 could cooperate with each other in the pathogenesis
of human endometrial carcinoma remains unknown but
is an intriguing and biologically important question.
Nevertheless, these data suggest that TrkB-dependent
STAT3 activation is an important event in regulating
miR-204 transcription in endometrial cancer cells and
possibly other cancer types.
MiR-204 has been previously shown to be greatly
downregulated in endometrioid adenocarcinoma tissues by
human miRNA microarray [18]. In contrast, a more recent
study showed that miR-204 is upregulated in the serum of
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tion of miR-204 is complex. Our results are consistent with
the former study in showing that miR-204-5p expression
in endometrial carcinoma tissues is significantly lower than
that in the normal endometrium. Furthermore, we present
the first direct evidence that reduced expression of miR-
204-5p is significantly associated with lymph node metasta-
sis. Our results support the possibility that miR-204-5p
may constitute a potential biomarker for good prognosis of
endometrial cancer, and therapeutic approaches targeting
elevated levels of miR-204-5p should be explored as a novel
approach to improve the clinical outcomes of endometrial
carcinoma patients.
The characterization of miR-204-5p function, to
date, has been limited, although several mRNA targets
have been identified that are important in normal cell
development, including MEIS1, HOXA9, MEIS2, RUNX2,
SIRT1 and Mcl-1 [43-47]. MiR-204-5p has been reported
to act as a tumor suppressor in a variety of cancers through
different mechanisms. MiR-204 also targets forkhead
box C1 (FOXC1), which regulates metastasis and invasion
in human endometrial cancer-derived HEC-1A cells.
In endometrial cancer, decreased expression of miR-
204 causes dysfunctional regulation of FOXC1, which
results in enhanced metastasis and invasion of tumor
cells [19]. Recently, miR-204 has been suggested as a novel
predictor of outcome in neuroblastoma, functioning, at
least in part, by increasing the sensitivity to cisplatin through
direct targeting and downregulation of anti-apoptotic BCL2
and TrkB [48]. Consistent with the study, we determined
that miR-204-5p specifically targets the 3′UTR of TrkB,
resulting in a significant reduction of full-length TrkB
protein. Our results, therefore, provide evidence for
another distinct role of miR-204 in carcinogenesis and
further highlight the importance of miR-204 expression in
endometrial carcinoma. Interestingly, TrkB has also been
identified as a target of miR-200c, which was markedly
upregulated in endometrial carcinoma [49]. A TrkB con-
struct that is resistant to miR-200c is unable to induce
anoikis [50], which may explain our observation that there
was no apparent change in TrkB mRNA transcript levels
between endometrial carcinoma and normal tissues. Fur-
ther investigation is required to elucidate the underlying
mechanisms of miR-200, given that downstream compo-
nents of TrkB signaling, such as Twist and Snail 1, are also
targets of the miR-200 family [51]. However, it will be of
interest to also determine the potential functional contribu-





Overall, this study uncovers a novel regulatory circuitry
involving TrkB–STAT3–miR-204-5p that is critical to the
tumorigenicity of human endometrial carcinoma andindicates that reestablishing miR-204-5p expression could
be explored as a potential new therapy for this disease.
Materials and methods
Acquisition of tissue specimens
Primary tumor tissue samples were acquired from 110
treatment-naïve endometrial carcinoma patients who
underwent hysterectomy with lymph node dissection
at our institution between August 2009 and April 2012.
The resected specimens were histologically examined by
H&E and immunohistochemical staining. Among them,
primary fresh tissues were collected from 71 of 110 corre-
sponding patients immediately after surgical removal and
snap-frozen in liquid nitrogen until further use. Patient
demographic and baseline characteristics are shown in
Table 2. In addition, 25 normal endometrium samples
were obtained from patients who underwent hysterectomy
due to other diseases than endometrial carcinoma. Tumor
stage and grade were established according to the 2009
Federation International of Gynecology and Obstetrics
(FIGO) surgical staging system [52]. 110 formalin-fixed,
paraffin-embedded tissues were used for immunohisto-
chemistry, and 71 fresh frozen samples from the same pa-
tients were used for LCM/qRT-PCR analysis. Acquisition of
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Ethical Committee of the authors’ affiliated institution.
Laser capture microdissection (LCM)
Ten to 20 serial frozen sections of 8 μm thickness were
fixed in 70% ethanol for 2 min at −20°C and stained with
HistoGene using a frozen section staining kit (Applied
Biosystems, Foster City, CA). Then, the sections were
rinsed in ice-cold RNA nuclease-free water at −20°C
followed by incubation in xylene for 2 min at −20°C.
After the sections were air-dried, the targeted cells
were microdissected according to a UV cutting and
laser capture procedure using the LCM system (Lecia,
LMD 7000, Germany). Endometrial cancer cells and normal
epithelial cells were captured onto CapSureMacro LCMcap
(Applied Biosystems, Foster City, CA) to allow analysis
of differential expression between cancer cells and normal
endometrial cells.
Cells and transfections
Human endometrial cancer cell lines Ishikawa and HEC-1B
and human embryonic kidney 293 T cells were obtained
from the Chinese Academy of Sciences Committee Type
Culture Collection (Shanghai, China). IshikawaTrkB cells
stably expressing ectopic TrkB and HEC-1BshTrkB cells stably
expressing TrkB-specific short hairpin RNA (shRNA) were
previously described [9]. Cells were maintained at 37°C in a
humidified atmosphere containing 5% CO2 in Dulbecco’s
modified Eagle’s medium/F12 (Gibco, Auckland, NZ) sup-
plemented with 10% fetal bovine serum (FBS) (Invitrogen,
Carlsbad, CA).
For transfections, cells were seeded at 2 × 105 cells/well in
6-well plates and after growth overnight were transfected
with miR-204i, miR-204 m, miR-204 mimic negative con-
trol (miR-204 m NC), or miR-204 inhibitor negative control
(miR-204i NC) (all from GenePharma, Shanghai, China)
using Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA)Table 3 Oligonucleotide sequences used in the study










GV219 STAT3 vector 5′-CGCAAATGGGCGGTAGGCGTG-3′
GV254-hsa-miR-204 5′-AGCTGTACAAGTAAGCCTGATCATGTACCCAaccording to the manufacturer’s instructions. For siRNA
knockdown of TrkB or STAT3, we used siRNA against
TrkB (siTrkB) [53], or siRNA against STAT3 (siSTAT3)
[54]. A scrambled siRNA (siTrkB-NC) was used as control.
The sequences are listed in Table 3. Ishikawa cells were
co-transfected with miR-204i and siTrkB, or miR-204i and
siTrkB-NC using Lipofectamine2000.U0126 treatment
Cells were seeded at 1.0 × 105 cells per well of a 12-well
plate, containing 1.2 mL regular medium. The media
was then changed to phenol-red free medium with 0.5%
stripped FBS for incubation at 37°C overnight. Immediately
prior to treatment, the medium in the culture plates was
aspirated, triply washed with PBS and replaced with fresh
medium. U0126 (Cell Signaling Technology, Danvers, MA)
dissolved in DMSO was subsequently added to each well.
Concurrently, the same amount of DMSO was added to
the control wells.MiRNA microarray
Total cellular RNA was isolated using a mirVana miRNA
extraction Kit (Ambion, Austin, TX) according to the man-
ufacturer’s instruction and labeled and hybridized using the
Human MicroRNA Microarray Kit (Agilent Technologies,
Santa Clara, CA) according to the manufacturer’s protocol.
Hybridization signals were detected with an Agilent DNA
microarray scanner G2505C, and scan images were ana-
lyzed using Agilent feature extraction software (v10.7.3).
Data were analyzed using GeneSpring GX 12.0 software
(Agilent Technologies). Values < 0.01 were set to 0.01 and
each measurement was divided by the 75th percentile of all
measurements from the same samples. MiRNAs whose ex-
pression differed by at least 1.5-fold between Ishikawa and
IshikawaTrkB cells (or between HEC-1B and HEC-1BshTrkB)
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Total cellular RNA was extracted using Tri-reagent
(Molecular Research Center; Cincinnati, OH). For miRNA
analysis, mature miRNA was reverse-transcribed from total
RNA using a TaqMan MicroRNA Reverse Transcription
kit. Real-time PCR was performed according to the manu-
facturer’s instructions. MiRNA expression was determined
using the 2(-△Ct) method and normalized against U6B. For
quantification of TrkB and TRPM3, cDNA was generated
using a Prime Script RT reagent Kit (TaKaRa; Dalian,
China), and real-time PCR was performed on an ABI
Prism 7000 Sequence Detection System with SYBR
Premix Ex Taq (TaKaRa). The primer sequences are
listed in Table 4. All experiments were performed in
triplicate at least three times independently.Chromatin immunoprecipitation (ChIP)-PCR
Chromatin immunoprecipitation (ChIP) assays were per-
formed as previously described [22] using anti-phospho-
STAT3 antibody (Tyr705) or rabbit isotype IgG (both from
Cell Signaling Technology, Danvers, MA). STAT3-binding
sites surrounding TRPM3 were predicted using in silico
analysis (University of California, Santa Cruz Genome
Browser and ENCODE database) as depicted previously
[22] and by quantitative real-time PCR using SYBR green
(Takara). Enrichment was calculated using the comparative
Ct method and primers used are shown in Table 4 and
were analyzed for specificity, linearity range, and efficiency
to accurately evaluate occupancy (percentage of immuno-
precipitation/input). VEGF was used as positive control and






TRPM3 UP1 Forward 5′-AACTCATCCCTGGAAGCAAACTGC-3′
Reverse 5′-TTTGGGCCTCAAGGAAGCAAACTG-3′
TRPM3 DW1 Forward 5′-ATGTTCCAGGAAGAGGGAACAGCA-3′
Reverse 5′-TTCTACCCAGAACCTTCCTTCCCA-3′





Reverse 5′-AGGTCCAGACGCAGGATGGCATG-3′Cell proliferation and clonogenic assays
For cell proliferation studies, cells were plated at 1 ×
103 cells/well in 96-well plates after 24-h serum starva-
tion. Cell viability was determined at the appropriate
time points using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium (MTT) assays with commercially
available kits (Sigma; St. Louis, MO). Absorbance was
measured at 490 nm using a Spectra Max 190 microplate
reader (BIO-RAD; Hercules, CA). For clonogenic survival
assays, cells were seeded at 2 × 103 cells/plate in 6 well
plates. After 2 weeks, cell colonies were stained with
0.1% crystal violet and counted.
Cell migration and invasion assays
Cells were plated serum-free at a density of 2 × 105/well
in invasion chambers (8 μm pore size; BD Biosciences,
San Jose, CA) with or without Matrigel-coating. Medium
containing 10% FBS was added into 24-well plates as
a chemoattractant. After 6 h (migration assay) or 24 h
incubation (invasion assay), cells were fixed with 4%
paraformaldehyde for 1 h. Cells on the apical side of
each insert were removed by mechanical scraping. Cells that
migrated to the basal side of the membrane were stained
with 0.1% crystal violet, visualized and counted under a
Leica DMI 3000B microscope at 200 ×magnification.
Immunoblotting assays
For Western blotting assays, conducted as previously
depicted [9], antibodies against the following proteins
were used: TrkB and phospho-TrkB (both from Abcam),
phospho-P44/42 MAPK (thr204/tyr204), P44/42 MAPK,
phospho-JAK2 (tyr1007/1008), JAK2, phospho-STAT3
(tyr705) and STAT3 (all from Epitomics). Protein bands
were visualized by enhanced chemiluminescence (Pierce
Biotechnology) and protein expression was normalized
against β-actin.
Luciferase assays
A DNA fragment containing a partial wildtype or mutant
3′UTR of TrkB was cloned into the pMIRGLO-REPORT
luciferase vector (Ambion) and the resultant vectors were
designated pMIRGLO-TrkB-3′UTR-WT and pMIRGLO-
TrkB-3′UTR-MT, respectively. We performed the lucifer-
ase assays using 293 T cells transiently transfected with
Renilla constructs (as an internal control) or plasmids
pMIRGLO-TrkB-3′UTR-WT or pMIRGLO-TrkB-3’UTR-
MT with or without miR-204 m or miR-204 m NC using
the Dual Luciferase Assay system following the manufac-
turer’s instructions (Promega, Madison, WI). All luciferase
activity readings were normalized relative to the activity of
the Renilla luciferase control and the results were expressed
as relative luciferase activity (Firefly LUC/Renilla LUC).
All experiments were performed in triplicate at least 3
times independently.
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cell lines
The lentivirus vector expressing miR-204-5p was prepared
using the Lenti-miR-204 miRNA Precursor Expression
Construct according to the manufacturer’s protocol
(Genechem, Shanghai) (Additional file 4: Figure S4A).
Stable IshikawaTrkB cells containing the lentivirus vector
carrying miR-204 or scramble hairpin control (Genechem)
were established after selection with appropriate antibiotics.
Xenograft assays
For xenograft experiments, sixteen 5-week old female
BALB/c nude mice (Chinese Academy of Sciences,
Shanghai, China) were injected subcutaneously with
5 × 106 IshikawaTrkB miRNA NC and IshikawaTrkB miR-204
cells, respectively, in the nape. Tumor size was monitored
every 4 days by measuring the length and width with cali-
pers, and tumor volumes were calculated with the formula:
(L ×W2) × 0.5 mm3, where L is the length and W is the
width of each tumor. At the completion of the experiment,
mice were sacrificed and the tumors were weighed, dis-
sected, measured and photographed. The study protocol
was approved by the local institution review board. The
mice used in this experiment were maintained under spe-
cific pathogen-free conditions and handled in accordance
with the NIH Animal Care and Use Committee regulations.
Immunohistochemistry and in situ hybridization
Paraffin embedded endometrial cancer and normal
endometrium tissue sections (4 μm) were processed
for immunohistochemistry as previously described [9].
Briefly, after deparaffinization and dehydration, specimens
were boiled in 10 mM sodium citrate buffer to unmask
antigens. Specimens were then blocked and incubated with
primary antibody overnight at 4°C. Antibody binding was
detected using Envision reagents (Boster bioengineering,
Wuhan, China) according to the manufacturer’s instruc-
tions. For evaluation of TrkB expression, staining inten-
sity was scored as 0 (negative), 1 (weak), 2 (medium), or
3(strong). The extent of staining was scored as 0 (0%), 1
(1%–25%), 2 (26%–50%), 3 (51%–75%), or 4 (76%–100%),
according to the percentage of the positively stained
areas in relation to the whole tumor area. The sum of
the intensity score and the extent score was used as the
final staining score (0–7) [55]. The results were assessed
by two pathologists who were blinded to details regarding
patient background.
Additionally, tissue sections (4 μm) of mouse xenografts
were routinely prepared and immunohistochemistry
was performed using standard avidin-biotin techniques.
Anti-TrkB antibody (Abcam) and anti-phospho-STAT3
antibody (Epitomics) were used for the procedure. Brown
staining of nuclei was regarded as positive. For in situ
hybridization, sections of mouse xenografts were dewaxedand rehydrated, followed by digestion with proteinase
K. A 5′ digoxin-labeled locked nucleic acid-modified
miR-204-5p probe (Ambion Life Technologies,) was in-
cubated on coverslips at 37°C overnight. Then, the sections
were incubated with anti-digoxin antibody (Boster) at 37°C
for 1 hour, followed by staining with nitro blue tetrazolium⁄-
bromo-4-chloro-3-indolylphosphate. MiRNA-204-5p in the
cytoplasm was stained purple.
In silico analysis of miR-204 and OS of UCEC patients
We performed an in silico analysis of the association be-
tween miR-204 and OS of UCEC patients using pub-
lished data from the Cancer Genome Atlas network [56]
(Additional file 5). Clinical information was downloaded
from the Additional file 5 “datafile.S1.1.KeyClinicalData.
xls” and miRNA expression profiling by miR-seq was
downloaded from the Additional file 5 “bcgsc.ca_UCEC.
Illumina_miRNASeq.tar” [56]. The RPKM value of miR-
NAs in each sample was used to construct the expres-
sion profile for hsa-miR-204 and the median of miR-204
expression was used as the cutoff value for high and low
expression of miR-204.
Statistical analysis
Data were presented as mean ± SD and analyzed by the
SPSS 16.0 software (SPSS Inc., Chicago, IL). Student’s t-test
was used for comparison between two groups, and one-
way ANOVA followed by post-hoc Turkey’s test was used
for comparison among multiple groups. Correlation was
analyzed by Spearman test, and OS was assessed using
standard log-rank test and by the Kaplan-Meier method.
All P-values are two-sided, and P-values less than 0.05 in-
dicated statistically significant difference. Each experiment
was performed as least three times independently.
Additional files
Additional file 1: Figure S1. Predicted miR-204 binding site in the TrkB
3′UTR. (A) Alignment of the predicted miR-204 binding site in the TrkB
3′UTR across five different species. The seed sequence is shaded in white
(upper panel) or labeled in blue (lower panel). (B) 293 T cells were
co-transfected with pMIRGLO-TrkB-3′UTR-MT and STAT3 vector (GV219) or
empty vector. Luciferase activities are shown as mean ± SD of at least
three independent experiments done in triplicate. NS, P > 0.05.
Additional file 2: Figure S2. Effect of MAPK pathway inhibition on
miR-204-5p expression. (A) IshikawaTrkB and HEC-1B cells were treated
with MAPK inhibitor U0126 (10 μM) or DMSO (control), and phospho-P44/
42 were assessed by Western blotting assays. (B and C) Inhibition of P44/42
MAPK has no effect on miR-204-5p expression in IshikawaTrkB and HEC-1B
cells. Data are expressed as mean ± SD of at least three independent
experiments. NS, P > 0.05.
Additional file 3: Figure S3. TrkB promotes while miR-204-5p
suppresses the clonogenic growth, migration and invasion of endometrial
cancer cells. (A) Upper and lower panel shows representative images of
colony formation in IshikawaTrkB and HEC-1BshTrkB cells. (B) Migrated cells on
the lower surface of the Transwell filter were stained and photographed,
200×. (C) Invasive cells on the lower surface of the Transwell filter were
stained and photographed, 200 × .
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http://www.molecular-cancer.com/content/12/1/155Additional file 4: Figure S4. Structure of the miR-204 plasmid and the
proliferation index in xenograft tumor tissues. (A) Structure of the
miR-204 lentiviral plasmid and its inserted primer sequence. (B) Ki67 and
PCNA protein expression in the nuclei of tumor cells transduced with this
plasmid. Bars show mean ± SD. **P < 0.01.
Additional file 5: Clinical patient information conducted by The
Cancer Genome Atlas (TCGA) network.
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